Abstract
One isoform of the 14-3-3 family, 14-3-3σ, plays a crucial role in the G2 checkpoint by sequestering Cdc2-cyclinB1 in the cytoplasm, and the expression of 14-3-3σ is frequently lost in breast cancers. This loss of expression is thought to cause a G2 checkpoint defect, resulting in chromosomal aberrations. Since lung cancers frequently carry numerous chromosomal aberrations, we examined the DNA methylation status and expression level of the 14-3-3σ gene in 37 lung cancer cell lines and 30 primary lung tumor specimens. We found that small cell lung cancer (SCLC) cell lines frequently showed DNA hypermethylation (9 of 13 lines, 69%), and subsequent silencing of the 14-3-3σ gene. Among non-small cell lung cancers (NSCLC), large cell lung cancer cell lines showed frequent hypermethylation and silencing of 14-3-3σ (4 or 7 lines, 57%). In contrast, in other NSCLC cell lines, hypermethylation occurred very rarely (1 of 17 lines, 6%). All eight primary SCLC specimens examined also showed a loss or significant reduction in 14-3-3σ expression in vivo, while a loss or reduction of 14-3-3σ expression was very rare in primary NSCLC specimens (1 of 22 tissues, 5%). This is the first description that indicates lung cancers frequently show significant inactivation of the 14-3-3σ gene mainly due to DNA hypermethylation in SCLC, but rarely in NSCLC, suggesting involvement of the 14-3-3σ gene in lung tumorigenesis in a histological type-specific manner.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B . 1999 Nature. 401: 616–620
Clark SJ, Harrison J, Paul CL, Frommer M . 1994 Nucleic Acids Res. 22: 2990–2997
Dhar S, Squire JA, Hande MP, Wellinger RJ, Pandita TK . 2000 Mol. Cell. Biol. 20: 7764–7772
Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR, Sukumar S . 2000 Proc. Natl. Acad. Sci. USA 97: 6049–6054
Haruki N, Harano T, Masuda A, Kiyono T, Takahashi T, Tatematsu Y, Shimizu S, Mitsudomi T, Konishi H, Osada H, Fujii Y, Takahashi T . 2001 Am. J. Pathol. 159: 1345–1352
Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B . 1997 Mol. Cell 1: 3–11
Iwata N, Yamamoto H, Sasaki S, Itoh F, Suzuki H, Kikuchi T, Kaneto H, Iku S, Ozeki I, Karino Y, Satoh T, Toyota J, Satoh M, Endo T, Imai K . 2000 Oncogene 19: 5298–5302
Kelley M, Nakagawa K, Steinberg S, Mulshine J, Kamb A, Johnson B . 1995 J. Natl. Cancer Inst. 87: 756–761
Konishi H, Nakagawa T, Harano T, Mizuno K, Saito H, Masuda A, Matsuda H, Osada H, Takahashi T . 2002 Cancer Res. 62: 271–276
Minna J, Sekido Y, Fong K, Gazdar A . 1997 Cancer Principles & Practice of Oncology Vol 1: Devita Jr, V, Hellman S & Rosenberg S (eds) Philadelphia: Lippincott-Raven pp 849–857
Nomoto S, Haruki N, Tatematsu Y, Konishi H, Mitsudomi T, Takahashi T . 2000 Genes Chromosomes Cancer 28: 342–346
Osada H, Hasada K, Inazawa J, Uchida K, Ueda R, Takahashi T, Takahashi T . 1996 Biochem Biophys Res. Commun. 229: 582–589
Osada H, Tatematsu Y, Masuda A, Saito T, Sugiyama M, Yanagisawa K, Takahashi T . 2001 Cancer Res. 61: 8331–8339
Sekido Y, Fong K, Minna J . 1998 Biochim. Biophys. Acta 1378: F21–F57
Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Imai K . 2000 Cancer Res. 60: 4353–4357
Takahashi T, Haruki N, Nomoto S, Masuda A, Saji S, Osada H, Takahashi T . 1999 Oncogene 18: 4295–4300
Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD . 1989 Science 246: 491–494
Testa J . 1996 Lung cancer: principles and practice Pass H, Mitchell J, Johnson D and Turrisi A (eds) Philadelphia: Lippincott-Raven pp 55–71
Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler Jr GB, Nieman L, Chrousos G, Pass H, Doppman J . 1991 Am. J. Surg. Pathol. 15: 529–553
Tsuchiya E, Furuta R, Wada N, Nakagawa K, Ishikawa Y, Kawabuchi B, Nakamura Y, Sugano H . 1995 J. Cancer Res. Clin. Oncol. 121: 577–581
Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S . 2001 Oncogene 20: 3348–3353
Acknowledgements
This work was supported in part by a Grant-in-Aid for the Second Term Comprehensive Ten-Year Strategy for Cancer Control and a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour, and Welfare, Japan; as well as a Grant-in-Aid for Scientific Research (C) from the Ministry of Education, Science, Sports and Culture, Japan. We would also like to thank Drs CC Harris (National Cancer Institute), LJ Old (Memorial Sloan Kettering Cancer Center), M Akiyama (Radiation Effect Research Foundation), and Y Hayata (Tokyo Medical University) for their generous gifts of cell lines.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Osada, H., Tatematsu, Y., Yatabe, Y. et al. Frequent and histological type-specific inactivation of 14-3-3σ in human lung cancers. Oncogene 21, 2418–2424 (2002). https://doi.org/10.1038/sj.onc.1205303
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205303
Keywords
This article is cited by
-
Using a machine learning approach to identify key prognostic molecules for esophageal squamous cell carcinoma
BMC Cancer (2021)
-
TTF-1/NKX2-1 binds to DDB1 and confers replication stress resistance to lung adenocarcinomas
Oncogene (2017)
-
Proteomic analysis of differentially expressed proteins in vitamin C-treated AGS cells
BMC Biochemistry (2013)
-
DNA methylation profiles delineate epigenetic heterogeneity in seminoma and non-seminoma
British Journal of Cancer (2012)
-
Aberrant upregulation of 14-3-3ơ expression serves as an inferior prognostic biomarker for gastric cancer
BMC Cancer (2011)